Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients (2013)
- Authors:
- Willrich, Maria Alice Vieira
- Rodrigues, Alice Cristina
- Cerda, Alvaro
- Genvigir, Fabiana Dalla Vecchia
- Arazi, Simone Sorkin
- Dórea, Egidio Lima
- Bernik, Marcia Martins Silveira
- Bertolami, Marcelo Chiara - Instituto Dante Pazzanese de Cardiologia (IDPC)
- Faludi, André Arpad - Instituto Dante Pazzanese de Cardiologia (IDPC)
- Largura, Alvaro
- Baudhuin, Linnea M
- Bryant, Sandra C
- Hirata, Mario Hiroyuki
- Hirata, Rosario Dominguez Crespo
- USP affiliated authors: DOREA, EGIDIO LIMA - HU ; HIRATA, MARIO HIROYUKI - FCF ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: HU; FCF
- DOI: 10.1016/j.cca.2013.03.007
- Subjects: EXPRESSÃO GÊNICA; HIPERCOLESTEROLEMIA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Clinica Chimica Acta
- ISSN: 0009-8981
- Volume/Número/Paginação/Ano: v. 421, p. 157-163, 2013
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: publisher-specific-oa
-
ABNT
WILLRICH, Maria Alice Vieira et al. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clinica Chimica Acta, v. 421, p. 157-163, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.cca.2013.03.007. Acesso em: 14 maio 2024. -
APA
Willrich, M. A. V., Rodrigues, A. C., Cerda, A., Genvigir, F. D. V., Arazi, S. S., Dórea, E. L., et al. (2013). Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clinica Chimica Acta, 421, 157-163. doi:10.1016/j.cca.2013.03.007 -
NLM
Willrich MAV, Rodrigues AC, Cerda A, Genvigir FDV, Arazi SS, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Largura A, Baudhuin LM, Bryant SC, Hirata MH, Hirata RDC. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients [Internet]. Clinica Chimica Acta. 2013 ; 421 157-163.[citado 2024 maio 14 ] Available from: https://doi.org/10.1016/j.cca.2013.03.007 -
Vancouver
Willrich MAV, Rodrigues AC, Cerda A, Genvigir FDV, Arazi SS, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Largura A, Baudhuin LM, Bryant SC, Hirata MH, Hirata RDC. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients [Internet]. Clinica Chimica Acta. 2013 ; 421 157-163.[citado 2024 maio 14 ] Available from: https://doi.org/10.1016/j.cca.2013.03.007 - Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
Informações sobre o DOI: 10.1016/j.cca.2013.03.007 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
